Health

We're trimming a health-care stock ahead of earnings — hedging our bets on business in China
We’re selling 95 shares of GE Healthcare at roughly $74. Following Wednesday’s trade, Jim Cramer’s Charitable Trust will own 1,150 shares of GEHC, reducing its weighting to 2.75% from 2.97%. The small trim we’re making in GE Healthcare with the stock up slightly in an otherwise rough tape does not change our belief in this […]
Read More
Biogen drops controversial Alzheimer's drug Aduhelm to focus on Leqembi, experimental treatments
The Biogen headquarters in Cambridge, Massachusetts, on Tuesday, Oct. 24, 2023. Vanessa Leroy | Bloomberg | Getty Images Biogen on Wednesday said it will discontinue the sale and development of its older and highly controversial Alzheimer’s drug Aduhelm to refocus the company’s efforts to treat the memory-robbing disease. The biotech company will focus on rolling […]
Read More
GSK posts blowout RSV vaccine sales, raises outlook as shots give big pharma a boost
Company logo of pharmaceutical company GlaxoSmithKline is seen at their Stevenage facility, Britain October 26, 2020. Dado Ruvic | Reuters GlaxoSmithKline on Wednesday lifted its long-term outlook following the smash-hit launch of its new RSV vaccine. The shot targeting the severe and in some cases life-threatening virus booked around £1.2 billion, or $1.5 billion, in […]
Read More
Norway's giant wealth fund touts possibility of Novo Nordisk, Eli Lilly joining the trillion-dollar club
A pharmacist displays boxes of Ozempic, a semaglutide injection drug used for treating type 2 diabetes made by Novo Nordisk, at Rock Canyon Pharmacy in Provo, Utah, U.S. March 29, 2023. George Frey | Reuters Norway’s giant wealth fund, the world’s largest, touted the possibility that Danish drugmaker Novo Nordisk and U.S. rival Eli Lilly […]
Read More
Healthy Returns: J&J, Merck and Bristol Myers Squibb are in the hot seat
Think a friend or colleague should be getting this newsletter? Share this link with them to sign up. Good afternoon! This is Annika Kim Constantino, and I cover the biotech and pharmaceutical industry for CNBC.com. Three names in the industry – Johnson & Johnson, Merck and Bristol Myers Squibb – face a pivotal few weeks […]
Read More
This little-known oncology stock could jump more than 70%, Citi says
Olema Oncology could be a standout player in developing therapies for women’s cancers, particularly in breast cancer, according to Citi Research. Analyst Yigal Nochomovitz initiated the clinical-stage biotech company at a buy/high risk rating, saying it has potential in developing a “next-gen endocrine therapy.” His price target of $20 implies shares could surge more than […]
Read More
Symptoms from excessive screen time cost the U.S. $73 billion a year, study finds
American workers are spending too much time looking at screens. More than 104 million people in the U.S., including nearly 70% of people working office jobs, spend upwards of seven hours a day looking at screens, according to a Tuesday report from the Deloitte Economics Institute and the American Optometric Association. As a result, symptoms […]
Read More
Pfizer beats earnings estimates as declining Covid business performs better than expected
Pfizer CEO Albert Bourla talks during a press conference with European Commission President Ursula von der Leyen after a visit to oversee the production of the Pfizer-BioNtech COVID-19 vaccine at the factory of U.S. pharmaceutical company Pfizer in Puurs, Belgium April 23, 2021. John Thys | Reuters Pfizer on Tuesday posted a surprise adjusted fourth-quarter […]
Read More
Big pharma is at a crossroads, as J&J, Merck and others prepare to lose heaps of revenue from blockbuster drugs
The New York Stock Exchange welcomes Johnson & Johnson (NYSE: JNJ) to the podium. NYSE Big pharmaceutical companies such as Bristol Myers Squibb, Merck and Johnson & Johnson face a looming threat that will put tens of billions of dollars in sales at risk between now and 2030, as blockbuster drugs will tumble off a […]
Read More
Merck, Johnson & Johnson CEOs agree to testify in Senate hearing on high drug prices
US Senator Bernie Sanders, Independent of Vermont, speaks during a rally by the People’s Action, protesting pharmaceutical companies’ lobbying against allowing Medicare to negotiate lower prescription drug prices, outside Pharmaceutical Research and Manufacturers of America (PhRMA) headquarters in Washington, DC, September 21, 2021. Saul Loeb | AFP | Getty Images The CEOs of Merck and […]
Read More